Publication details
Diagnostika a léčba hepatitidy D
| Title in English | Diagnosis and treatment of hepatitis D |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Profi Medicína |
| MU Faculty or unit | |
| Citation | |
| Web | https://profimedicina.cz/diagnostika-a-lecba-hepatitidy-d/ |
| Keywords | hepatitis D; diagnosis;treatment |
| Description | Hepatitis D virus (HDV) can co-infect a susceptible host with hepatitis B virus - HBV (co-infection) or superinfect a person chronically infected with HBV. HBV/HDV coinfection usually leads to acute hepatitis with a wide clinical spectrum ranging from an asymptomatic course to acute liver failure. However, only a small proportion of cases (around 2%) progress to chronicity. In contrast, superinfection with HDV on chronic HBV infection very often leads to severe acute hepatitis, which progresses to chronic hepatitis D (CHD) in up to 90% of cases, which is associated with more severe chronic outcomes than HBV monoinfection. CHD has been shown to progress more frequently and more rapidly to liver cirrhosis and hepatocellular carcinoma than HBV monoinfection. Bulevirtide (BLV) is a synthetic lipopeptide that binds to a receptor that is required for HDV to enter the hepatocyte. It is the first antiviral drug against HDV and in July 2020 BLV received conditional approval for use for the treatment of CHD with compensated liver disease from the European Medicines Agency (EMA), with a recommendation to continue BLV therapy at a dose of 2 mg daily until clinical benefit is seen. The conditional registration was changed to standard registration in July 2023. |